Denosumab

Breast Diseases

Alliance for Clinical Trials in Oncologymonoclonal_antibodyPhase 3Active

B

57/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 45/ 100
Competitive Position: 81/ 100

Competitive context

23 Active assets in the Breast Diseases cohort.

Asset / Sponsor	Phase	Rating
TRASTUZUMAB Incepta Pharmaceuticals Ltd	Phase 3	BB
SACUBITRIL VALSARTAN Silesian Centre for Heart Diseases	Phase 4	BB
Olaparib AstraZeneca	Phase 2	BB
Vinorelbine Sun Yat-sen University	Phase 2	BB
Capecitabine University of Southern California	Phase 3	B

View all 46 →

Same molecule, other indications

Denosumab is also rated in:

metastatic carcinoma in the boneDormant

BBB

Indicative ·

79 / 100

breast carcinomaDormant

BB

Indicative ·

70 / 100

castration-resistant prostate carcinomaDormant

BB

Indicative ·

68 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.